Can data from one CAR T-cell therapy be used to inform FDA’s review of other CAR T products?
CAR T-cell therapies have been used to treat cancer patients since 2011, but infection-related adverse events remain a significant hurdle. Often, fever is one of the earliest warning signs of clinical deterioration and a potentially life-threatening condition.
A study published in Blood Advances demonstrates that patients with blood cancers experienced a significant improvement in their reported well-being six months after receiving CAR T-cell therapy.
Dwight Tosh had grown so weak that he was unable to walk. Still, doctors at the rural Arkansas hospital—where he lay in bed for weeks in 1962—were unable to diagnose him.
NYU College of Dentistry has received a gift from the Leukemia & Lymphoma Society to create a pilot program to provide financial support for dental care for U.S. military veterans with blood cancer.
Mission Bio Inc. has created the first assay capable of determining measurable residual disease in cancer down to the level of individual cells.
Researchers at Winship Cancer Institute of Emory University found that COVID-19 vaccines are much less effective for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia, particularly those ages 65 and older. After vaccination, many of these patients produced low or no antibodies that bind or neutralize SARS-CoV-2 and its variants of concern, particularly Omicron.
Scientists at Yale Cancer Center have discovered consequences of specific gene mutations that play a role in the development of myelodysplastic syndromes and acute myeloid leukemia.
Vanderbilt study: World Trade Center responders at higher risk for blood cancer-associated mutations
Scientists from Vanderbilt-Ingram Cancer Center and researchers from New York determined that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease.
Faith E. Davies was named the inaugural director of the Center for Blood Cancers at NYU Langone Health’s Perlmutter Cancer Center.
